TY - JOUR A1 - Jockel-Schneider, Yvonne A1 - Schlagenhauf, Ulrich A1 - Petsos, Hari A1 - Rüttermann, Stefan A1 - Schmidt, Jana A1 - Ziebolz, Dirk A1 - Wehner, Christian A1 - Laky, Markus A1 - Rott, Thea A1 - Noack, Michael A1 - Noack, Barbara A1 - Lorenz, Katrin T1 - Impact of 0.1% octenidine mouthwash on plaque re-growth in healthy adults: a multi-center phase 3 randomized clinical trial JF - Clinical Oral Investigations N2 - Objectives To investigate plaque inhibition of 0.1% octenidine mouthwash (OCT) vs. placebo over 5 days in the absence of mechanical plaque control. Materials and methods For this randomized, placebo-controlled, double-blind, parallel group, multi-center phase 3 study, 201 healthy adults were recruited. After baseline recording of plaque index (PI) and gingival index (GI), collection of salivary samples, and dental prophylaxis, subjects were randomly assigned to OCT or placebo mouthwash in a 3:1 ratio. Rinsing was performed twice daily for 30 s. Colony forming units in saliva were determined before and after the first rinse. At day 5, PI, GI, and tooth discoloration index (DI) were assessed. Non-parametric van Elteren tests were applied with a significance level of p < 0.05. Results Treatment with OCT inhibited plaque formation more than treatment with placebo (PI: 0.36 vs. 1.29; p < 0.0001). OCT reduced GI (0.04 vs. placebo 0.00; p = 0.003) and salivary bacterial counts (2.73 vs. placebo 0.24 lgCFU/ml; p < 0.0001). Tooth discoloration was slightly higher under OCT (DI: 0.25 vs. placebo 0.00; p = 0.0011). Mild tongue staining and dysgeusia occurred. Conclusions OCT 0.1% mouthwash inhibits plaque formation over 5 days. It therefore can be recommended when regular oral hygiene is temporarily compromised. Clinical relevance When individual plaque control is compromised, rinsing with octenidine mouthwash is recommended to maintain healthy oral conditions while side effects are limited. KW - octenidine KW - mouthrinse KW - bacterial counts KW - plaque index KW - gingival index KW - discoloration index Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-307629 SN - 1432-6981 SN - 1436-3771 VL - 25 IS - 7 ER - TY - JOUR A1 - Walther, Kay-Arne A1 - Gonzales, José Roberto A1 - Gröger, Sabine A1 - Ehmke, Benjamin A1 - Kaner, Dogan A1 - Lorenz, Katrin A1 - Eickholz, Peter A1 - Kocher, Thomas A1 - Kim, Ti-Sun A1 - Schlagenhauf, Ulrich A1 - Koch, Raphael A1 - Meyle, Jörg T1 - The role of polymorphisms at the Interleukin-1, Interleukin-4, GATA-3 and Cyclooxygenase-2 genes in non-surgical periodontal therapy JF - International Journal of Molecular Sciences N2 - Periodontitis is a multifactorial disease. The aim of this explorative study was to investigate the role of Interleukin-(IL)-1, IL-4, GATA-3 and Cyclooxygenase-(COX)-2 polymorphisms after non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole) and subsequent maintenance in a Caucasian population. Analyses were performed using blood samples from periodontitis patients of a multi-center trial (ClinicalTrials.gov NCT00707369=ABPARO-study). Polymorphisms were analyzed using quantitative real-time PCR. Clinical attachment levels (CAL), percentage of sites showing further attachment loss (PSAL) ≥1.3 mm, bleeding on probing (BOP) and plaque score were assessed. Exploratory statistical analysis was performed. A total of 209 samples were genotyped. Patients carrying heterozygous genotypes and single-nucleotide-polymorphisms (SNP) on the GATA-3-IVS4 +1468 gene locus showed less CAL loss than patients carrying wild type. Heterozygous genotypes and SNPs on the IL-1A-889, IL-1B +3954, IL-4-34, IL-4-590, GATA-3-IVS4 +1468 and COX-2-1195 gene loci did not influence CAL. In multivariate analysis, CAL was lower in patients carrying GATA-3 heterozygous genotypes and SNPs than those carrying wild-types. For the first time, effects of different genotypes were analyzed in periodontitis progression after periodontal therapy and during supportive treatment using systemic antibiotics demonstrating a slight association of GATA-3 gene locus with CAL. This result suggests that GATA-3 genotypes are a contributory but non-essential risk factor for periodontal disease progression. KW - periodontitis KW - polymorphisms KW - risk factor KW - periodontal therapy KW - antibiotics KW - GATA-3 KW - Interleukin-1 KW - Interleukin-4 KW - Cyclooxygenase-2 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284386 SN - 1422-0067 VL - 23 IS - 13 ER - TY - JOUR A1 - Matern, Johannes A1 - Koch, Raphael A1 - Petersmann, Astrid A1 - Kocher, Thomas A1 - Eickholz, Peter A1 - Lorenz, Katrin A1 - Kim, Ti‐Sun A1 - Meyle, Jörg A1 - Kaner, Doğan A1 - Schlagenhauf, Ulrich A1 - Gravemeier, Martina A1 - Harks, Inga A1 - Ehmke, Benjamin T1 - Effect of periodontal therapy on adipokine biomarkers in overweight JF - Journal of Clinical Periodontology N2 - Aim The aim of this study was to evaluate the effect of non‐surgical periodontal therapy on circulating levels of the systemic inflammation‐associated biomarkers orosomucoid (ORM), high‐sensitivity C‐reactive protein (hsCRP), chemerin, and retinol‐binding protein 4 (RBP4) in overweight or normal‐weight patients with periodontitis at 27.5 months after therapy. Materials and methods This exploratory subanalysis includes patients from the ABPARO‐trial (ClinicalTrials.gov NCT00707369). The per‐protocol collective provided untreated periodontitis patients with high (≥28 kg/m\(^{2}\)) or moderate (21–24 kg/m\(^{2}\)) BMI. Out of the per‐protocol collective, 80 patients were randomly selected and stratified for BMI group, sex, and treatment group (antibiotics/placebo), resulting in 40 overweight and normal‐weight patients. Patients received non‐surgical periodontal therapy and maintenance at 3‐month intervals. Plasma samples from baseline and 27.5 months following initial treatment were used to measure the concentrations of ORM, hsCRP, chemerin, and RBP4. Results At the 27.5‐month examination, ORM and hsCRP decreased noticeably in the overweight group (ORM: p = .001, hsCRP: p = .004) and normal‐weight patients (ORM: p = .007, hsCRP: p < .001). Chemerin decreased in the overweight group (p = .048), and RBP4 concentrations remained stable. Conclusion Non‐surgical periodontal therapy reduced systemically elevated inflammation‐associated biomarkers in periodontitis patients. These improvements were more pronounced in overweight patients than in normal‐weight patients. KW - chemerin KW - orosomucoid KW - overweight KW - periodontitis KW - retinol‐binding protein 4 Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-215546 VL - 47 IS - 7 SP - 842 EP - 850 ER -